GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The dual antiplatelet therapy based on aspirin plays an important role in the treatment of
patients with coronary heart disease. Although aspirin is widely used and effective, it has
many limitations in the long-term including increased risk of bleeding. In patients with
coronary heart disease and gastroesophageal reflux disease, the symptoms of gastroesophageal
reflux are usually aggravated after the application of aspirin. As an antiplatelet drug,
indobufen can reversibly and selectively inhibit platelet cyclooxygenase-1 (COX-1), thereby
blocking the synthesis of thromboxane B2 (TXB2) and exerting its antiplatelet effect, and it
does not affect the production of prostaglandins and endothelial prostacyclins in
gastrointestinal mucosa. It has less gastrointestinal injury and lower risk of bleeding. This
project is to study the effects of indobufen or aspirin on gastric acid secretion and
gastroesophageal reflux in patients with coronary heart disease and gastroesophageal reflux
disease treated with dual antiplatelet therapy.